Investigators calculated that the new assay, which includes 67 SNPs, could offer a 50 percent improvement over previous methods if used in newborn screening.
The 72-SNP score is for men of European ancestry who don't have mutations in high penetrance risk genes or mutations in genes associated with aggressive disease.
The Australian molecular diagnostics firm received 265 test samples during the quarter, including 140 tests issued to Ohio State University as part of an agreement.
Geneticure has raised around $1.1 million to fund the study, which may very well be the largest prospective RCT for personalization of high blood pressure treatment.
The test is performed in less than an hour using a buccal cheek swab, and runs on Genedrive’s hand-held real-time PCR instrument.